CN110678178B - Mk2抑制剂的形式和组合物 - Google Patents

Mk2抑制剂的形式和组合物 Download PDF

Info

Publication number
CN110678178B
CN110678178B CN201880032086.2A CN201880032086A CN110678178B CN 110678178 B CN110678178 B CN 110678178B CN 201880032086 A CN201880032086 A CN 201880032086A CN 110678178 B CN110678178 B CN 110678178B
Authority
CN
China
Prior art keywords
compound
disease
disorder
complex
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880032086.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110678178A (zh
Inventor
J·韩
L·黄
U·杰恩
Y·李
J·马罗那
K·莫尔特
C·帕巴
A·L·卢切尔曼
J·徐
D·邹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Celgene Avilomics Research Inc filed Critical Bristol Myers Squibb Co
Publication of CN110678178A publication Critical patent/CN110678178A/zh
Application granted granted Critical
Publication of CN110678178B publication Critical patent/CN110678178B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
CN201880032086.2A 2017-03-16 2018-03-15 Mk2抑制剂的形式和组合物 Active CN110678178B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
US62/472,015 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (2)

Publication Number Publication Date
CN110678178A CN110678178A (zh) 2020-01-10
CN110678178B true CN110678178B (zh) 2023-10-03

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880032086.2A Active CN110678178B (zh) 2017-03-16 2018-03-15 Mk2抑制剂的形式和组合物

Country Status (8)

Country Link
US (2) US10882867B2 (enExample)
EP (1) EP3595658A4 (enExample)
JP (2) JP2020514360A (enExample)
CN (1) CN110678178B (enExample)
AU (1) AU2018236286B2 (enExample)
CA (1) CA3054823A1 (enExample)
MX (1) MX393600B (enExample)
WO (1) WO2018170199A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201902326XA (en) 2014-09-17 2019-04-29 Celgene Car Llc Mk2 inhibitors and uses thereof
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN102753179A (zh) * 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
CN103717597A (zh) * 2011-04-21 2014-04-09 原真股份有限公司 作为激酶抑制剂的杂环化合物
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
WO2014210319A2 (en) * 2013-06-26 2014-12-31 The Trustees Of Columbia University In The City Of New York Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
MX2017008994A (es) 2015-01-08 2018-09-18 Moerae Matrix Inc Formulacion de peptidos inhibidores mk2.
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
JP2020514361A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN102753179A (zh) * 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103717597A (zh) * 2011-04-21 2014-04-09 原真股份有限公司 作为激酶抑制剂的杂环化合物
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕扬等."晶型药物".《晶型药物》.人民卫生出版社,2009,第6、24-25、138页. *

Also Published As

Publication number Publication date
US11629153B2 (en) 2023-04-18
EP3595658A4 (en) 2020-11-25
JP2023017840A (ja) 2023-02-07
US20200148701A1 (en) 2020-05-14
EP3595658A1 (en) 2020-01-22
US10882867B2 (en) 2021-01-05
WO2018170199A1 (en) 2018-09-20
US20210198276A1 (en) 2021-07-01
AU2018236286B2 (en) 2022-02-17
AU2018236286A1 (en) 2019-09-19
JP2020514360A (ja) 2020-05-21
MX393600B (es) 2025-03-24
CN110678178A (zh) 2020-01-10
CA3054823A1 (en) 2018-09-20
MX2019010643A (es) 2019-10-17

Similar Documents

Publication Publication Date Title
CN110678178B (zh) Mk2抑制剂的形式和组合物
DK2477628T3 (en) Preparation of crystalline hemihydratformer of dihydropyrazolopyrimidinon
AU2017348259A1 (en) Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
CA3026602A1 (en) Pyrrolopyrimidine crystal for preparing jak inhibitor
JP2020511468A (ja) Ｍｋ２阻害剤の重水素化アナログおよびその使用
US20090076272A1 (en) Polymorphs of eszopiclone malate
EP2585466A1 (en) Polymorphs of osi-906
RS60939B1 (sr) Čvrsti oblici soli nilotiniba
JP2025538371A (ja) 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法
KR20250130412A (ko) 화합물 a의 염과 결정형, 및 그 제조 방법과 용도
AU2011284341A1 (en) N-Methylformamide solvate of dasatinib
WO2021030386A1 (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
HK1256825A1 (zh) 取代的5，6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物的固体形式
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
JP7776258B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
CN120917029A (zh) 结晶形式
WO2019056003A1 (en) CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
KR20190029601A (ko) 고체 형태의 ttk 억제제
EP3819296A1 (en) Method for producing diarylpyridine derivatives
KR20160143842A (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물의 염 및 다형체
JP7289017B2 (ja) ピロリジニルウレア誘導体の結晶及びその使用
WO2019057121A1 (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
WO2025011618A9 (zh) 噻唑并吡嗪类化合物的盐或其结晶及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230625

Address after: new jersey

Applicant after: BRISTOL-MYERS SQUIBB Co.

Address before: Bermuda Hamilton

Applicant before: CELGENE AVILOMICS RESEARCH, Inc.

GR01 Patent grant
GR01 Patent grant